NKTR Nektar Therapeutics

36.51
-1.49  -4%
Previous Close 38
Open 37.45
Price To Book 3.53
Market Cap 6319341784
Shares 173,085,231
Volume 1,705,663
Short Ratio
Av. Daily Volume 2,566,846

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167941
  2. 8-K - Current report 181166628
  3. 8-K - Current report 181098372
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181002999
  5. 8-K - Current report 181001529

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data at SITC November 2018 noted ORR 53%.
NKTR-214 + OPDIVO (nivolumab) - PIVOT-02
Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers
Phase 1/2 commencement of dosing announced September 12, 2017. Initial data presented at ASCO 2018
NKTR-214 + TECENTRIQ + KEYTRUDA (PROPEL)
Solid tumors - cancer
Phase 3 second trial did not meet endpoint - April 5, 2017.
Cipro DPI
Bronchiectasis
PDUFA date May 28, 2019.
NKTR-181
Lower back pain
Phase 3 data released November 24, 2017. Endpoints not met.
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 topline data mid March 2015 did not reach primary endpoint.
Etirinotecan pegol NKTR-102 (BEACON)
Cancer - Metastatic Breast Cancer
Approved November 16, 2015.
ADYNOVATE
Hemophilia A
Approved September 16, 2014.
MOVANTIK (Naloxegol)
Opioid-induced constipation (OIC)
Phase 1/2 trial initiation announced April 11, 2018.
NKTR-262 and NKTR-214 - REVEAL
Solid tumors
Phase 1b initiation announced May 8, 2018.
NKTR-358
Systemic lupus erythematosus (SLE)

Latest News

  1. See what the IHS Markit Score report has to say about Nektar Therapeutics.
  2. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – NKTR
  3. INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
  4. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CWH, HON, DY, ALGN and NKTR
  5. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline - December 31, 2018
  6. IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
  7. CLASS ACTION UPDATE for IGCC, NKTR and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  8. Nektar Therapeutics (NKTR): Are Hedge Funds Right About This Stock?
  9. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Jianpu, Nektar, Honeywell, and Fitbit and Encourages Investors to Contact the Firm
  10. Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit against Nektar Therapeutics, Inc.
  11. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm
  12. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, IGCC, NKTR, TSRO and APHA
  13. 8 Stocks With High Sharpe Ratios to Stomach Volatility
  14. SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
  15. NKTR NOTICE: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important Deadline in Class Action Seeking Investor Losses– NKTR
  16. Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Nektar Therapeutics, Inc.
  17. SHAREHOLDER ALERT: COST NKTR FIT RBBN SONS MGI ATUS CMCM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
  18. SHAREHOLDER DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167941
  2. 8-K - Current report 181166628
  3. 8-K - Current report 181098372
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181002999
  5. 8-K - Current report 181001529
  6. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 18945948
  7. S-8 - Securities to be offered to employees in employee benefit plans 18929601
  8. 8-K - Current report 18922373
  9. 8-K - Current report 18884730
  10. 8-K - Current report 18876958